Imezemic 1000mg Tablet SR

The sustained-release (SR) formulation ensures a steady plasma concentration, promoting improved adherence and minimizing fluctuations in blood glucose levels. Imezemic is typically administered once or twice daily, with or without food, as part of a comprehensive diabetes management plan that includes lifestyle modifications such as diet and physical activity. Clinical trials have demonstrated that Imeglimin effectively lowers HbA1c and fasting plasma glucose with a favorable safety profile.

Common adverse effects are generally mild and may include gastrointestinal disturbances such as nausea or diarrhea. Imezemic should be used cautiously in patients with renal impairment, and dose adjustments may be necessary. It is contraindicated in patients with type 1 diabetes or diabetic ketoacidosis. Regular monitoring of blood glucose and renal function is recommended during therapy to optimize treatment outcomes and ensure patient safety.